Морфологические изменения в печени экспериментальных животных на фоне сочетанного введения адрибластина и FOXO4-DRI

Abstract

Doxorubicin is actively used in scientific practice not only as a chemotherapeutic drug, but also as a senescence inducer due to its mechanism of action, namely, the blocking of mitosis, the development of mitochondrial dysfunction and DNA intercalation, which is most pronounced in labile cell populations. The senescent phenotype is currently considered as one of the possible options for the induction of prooncogenes, failure of repair processes and local inflammatory response. The combined use of senolytics together with chemotherapy drugs has been used for a long time (quercetin and dasatinib), however, the combination of peptide-based senolytics (FOXO4-DRI) with doxorubicin seems to be one of the most promising. This article discusses the combined use of FOXO4-DRI and doxorubicin in female and male mice in the early stages. As a result, microscopic examination showed a moderate protective effect of the senolytic peptide on the liver cell population, a decrease in the degree of leukocyte infiltration, and a decrease in the degree of fatty infiltration. There was a significant difference in responses between animals of different sexes.